BCAX — Bicara Therapeutics Inc. Common Stock stock price, charts and financials

QT81Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
22.59
+0.59+2.68%
OverviewShort InterestFilings
BCAXQT81Bicara Therapeutics Inc. Common Stock·NASDAQ
22.59+2.68%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+3.19%$14.87FTRE+1.55%$20.28NKTR+1.45%$68.36GHRS+3.50%$28.72RAPP+1.35%$41.95AGIO+2.00%$33.61ZBIO-1.08%$31.97GPCR-1.13%$35.10
Snapshot
Index-P/E-EPS (ttm)-Insider Own30.73%Shs Outstand65.70MPerf Week-2.21%
Market Cap1.48BForward P/E-EPS next Y-3.56Insider Trans-1.09%Shs Float36.30MPerf Month-9.35%
Enterprise Value1.07BPEG-EPS next Q-0.85Inst Own-Short Float29.88%Perf Quarter-1.44%
Income-138.00MP/S0.00EPS this Y-Inst Trans-Short Ratio14.98Perf Half Y22.71%
Sales0.00P/B3.70EPS next Y-4.35%ROA-36.19%Short Interest10.85MPerf YTD34.22%
Book/sh6.10P/C3.58EPS next 5Y-ROE-41.49%52W High30.99 -27.11%Perf Year100.80%
Cash/sh6.32P/FCF-EPS past 3/5Y-ROIC-42.98%52W Low10.30 119.32%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility4.88% 5.04%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-148.00%Oper. Margin0.00%ATR (14)1.28Perf 10Y-
Dividend Ex-Date-Quick Ratio11.59Sales Y/Y TTM-Profit Margin0.00%RSI (14)40.92Recom2.33
Dividend Gr. 3/5Y-Current Ratio11.59EPS Q/Q-64.00%SMA20-3.83%Beta1.02Target Price32.57
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-11.28%Rel Volume0.67Prev Close22.00
Employees103LT Debt/Eq0.00EarningsNov 09SMA2006.41%Avg Volume729.00KPrice22.59
IPO DateSep 13, 2024Option/ShortYes / YesEPS/Sales Surpr.-0.03% -Net Debt/EBITDA0.52Volume491,967Change2.68%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-18-26InitiatedBMO CapitalOutperform$35
Aug-12-26ReiteratedBTIGBuy$28 → $39
Aug-12-26ReiteratedWedbushOutperform$33
Aug-12-26ReiteratedMizuhoNeutral$18 → $20
Aug-12-26ReiteratedGoldman SachsNeutral$18 → $20
May-12-26ReiteratedMorgan StanleyOverweight$35 → $37
May-12-26ReiteratedGoldman SachsNeutral$14 → $18
May-11-26InitiatedGuggenheimBuy$42
Feb-11-26ReiteratedGoldman Sachs$14
Jan-08-26InitiatedBTIGBuy$28
Latest News· Times ET
Sep-03-26
Sep-03-2604:30AM
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-19-26
Aug-19-2601:56AM
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35Benzinga
Aug-14-26
Aug-14-2604:30AM
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-13-26
Aug-13-2611:37PM
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAXdefenseworld.net
Aug-12-26
Aug-12-2610:23AM
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20Benzinga
07:11AM
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwindsseekingalpha.com
04:34AM
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Resultsbenzinga.com
Aug-11-26
Aug-11-2607:57AM
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcriptseekingalpha.com
06:06AM
Bicara Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
Aug-04-26
Aug-04-2604:30AM
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ETglobenewswire.com
Jul-31-26
Jul-31-2605:00PM
Top movers in Friday's after hours sessionChartMill
Jul-28-26
Jul-28-2604:30AM
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directorsglobenewswire.com
Jul-02-26
Jul-02-2604:30AM
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Company

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
000—
Cost of Goods Sold Incl. D&A
000—
Gross Profit
000—
Selling, General and Administrative Excl. Other31199—
Research and Development1256431—
Other Operating Expense0-10—
Operating Income-156-82-40—
Interest Expense
000—
Unusual Expense
————
Non-Operating Income (Expense)1815-12—
Net Income Before Taxes-138-68-52—
Income Taxes
000—
Consolidated Net Income-138-68-52—
Net Income From Continuing Operations-138-68-52—
Net Income-138-68-52—
EPS (Recurring)-2.52-1.25-1.00—
EPS (Basic, Before Extraordinaries)-2.52-1.25-1.00—
EPS (Diluted)-2.52-1.25-1.00—
EBITDA-138-68-52—
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio
————
Gross Margin
————
Operating Margin
————
Net Margin
————
Shares Outstanding555452—
Market Capitalization926941——
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$33.50$26.78$20.05$13.33$6.61● Close Price0.00M1.20M2.40M3.60M4.80MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cohlhepp RyanPresident, COO & Interim CEOSep 08 '26Sale22.9017,500400,716181,641Sep 10
Cohlhepp RyanPresident, COO & Interim CEOSep 08 '26Option Exercise3.7917,50066,322199,141Sep 10
Hyep IvanChief Financial OfficerAug 10 '26Sale27.9712,500349,591129,855Aug 12
Mazumdar ClaireChief Executive OfficerAug 10 '26Option Exercise3.7910,00037,898372,152Aug 12
Mazumdar ClaireChief Executive OfficerAug 10 '26Sale27.9810,000279,750362,152Aug 12
Cohlhepp RyanPresident and COOAug 10 '26Option Exercise3.7918,75071,059200,391Aug 12
Cohlhepp RyanPresident and COOAug 10 '26Sale27.9818,750524,533181,641Aug 12
Hyep IvanChief Financial OfficerAug 10 '26Option Exercise3.7912,50047,373142,355Aug 12
Mazumdar ClaireChief Executive OfficerJul 10 '26Sale28.4210,000284,198362,152Jul 14
Mazumdar ClaireChief Executive OfficerJul 10 '26Option Exercise3.7910,00037,898372,152Jul 14
Cohlhepp RyanPresident and COOJul 09 '26Sale29.0053615,544181,641Jul 10
Cohlhepp RyanPresident and COOJul 08 '26Sale28.9828,214817,586182,177Jul 10
Cohlhepp RyanPresident and COOJul 08 '26Option Exercise3.7918,75071,059210,391Jul 10
Hyep IvanChief Financial OfficerJul 08 '26Option Exercise3.7925,00094,745157,855Jul 10
Hyep IvanChief Financial OfficerJul 08 '26Sale28.8528,000807,672129,855Jul 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.